You are here

Article Text

Article menu

Download PDFPDF

Research paper
Global evidence on the effect of point-of-sale display bans on smoking prevalence
Free
  1. Yanyun He1,
  2. Ce Shang2,
  3. Jidong Huang3,
  4. Kai-Wen Cheng1,2,
  5. Frank J Chaloupka1,2
  1. 1 University of Illinois, Chicago, Illinois, USA
  2. 2 Institute for Health Research and Policy, University of Illinois, Chicago, Illinois, USA
  3. 3 School of Public Health, Tobacco Center of Regulatory Science, Georgia State University, Atlanta, Georgia, USA
  1. Correspondence to Dr Ce Shang, Institute for Health Research and Policy, University of Illinois, Chicago, IL 60002, USA; cshang{at}uic.edu

Abstract

Background Since Iceland became the first country to impose a ban on point-of-sale (POS) tobacco product displays in 2001, 20 countries have implemented POS display bans as of 2016. This study examined the effect that POS display bans have on smoking prevalence.

Methods Data were sourced from Euromonitor International and the WHO MPOWER package for 2007–2014 from 77 countries worldwide. generalised linear models with country and year fixed effects were estimated to analyse the effect of POS display bans on smoking prevalence.

Results Having a POS display ban reduced overall adult daily smoking, male smoking and female smoking by about 7%, 6% and 9%, respectively.

Conclusions Having a POS display ban is likely to reduce smoking prevalence and generate public health benefits.

  • global health
  • public policy
  • advertising and promotion

https://doi.org/10.1136/tobaccocontrol-2017-053996

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors YH conducted the analyses and wrote the manuscript. CS, JH, K-WC and FJC contributed to study design and reports interpretation. The findings and conclusions in this article are those of the authors.

    • Funding Research reported in this publication was supported by grant number P50DA036128 from the NIH/NIDA and FDA Center for Tobacco Products (CTP).

    • Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.